Last reviewed · How we verify

NCT06618872: IDV of tau-PET

Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment

Recruiting now NA Last updated 23 December 2025
What this trial tests

NA trial testing PET/CT with RO958 (experimental) in Dementia in 120 participants. Currently enrolling.

Timeline
3 December 2024
Primary endpoint
30 August 2027
30 August 2027

Quick facts

Lead sponsorUniversity Hospital, Geneva
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposediagnostic
Enrollment120
Start date3 December 2024
Primary completion30 August 2027
Estimated completion30 August 2027
Sites2 locations across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Geneva

Who can join

Adults 50 to 85, any sex, with Dementia or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
    Harris GA, Hirschfeld LR, Gonzalez MI, Pritchard MC, et al · · 2025 · cited 8× · PMID 40462159 · DOI 10.1186/s13195-025-01775-x

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

Other University Hospital, Geneva trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06618872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing